Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Citations Over TimeTop 1% of 2005 papers

Abstract

Abstract Background Tamoxifen is widely used as endocrine therapy for oestrogen-receptor-positive breast cancer. However, many of these patients experience recurrence despite tamoxifen therapy by incompletely understood mechanisms. In the present report we propose that tamoxifen resistance may be due to differences in activity of metabolic enzymes as a result of genetic polymorphism. Cytochrome P450 2D6 ( CYP2D6 ) and sulfotransferase 1A1 ( SULT1A1 ) are polymorphic and are involved in the metabolism of tamoxifen. The CYP2D6*4 and SULT1A1*2 genotypes result in decreased enzyme activity. We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy. Methods The patients were genotyped using PCR followed by cleavage with restriction enzymes. Results Carriers of the CYP2D6*4 allele demonstrated a decreased risk of recurrence when treated with tamoxifen (relative risk = 0.28, 95% confidence interval = 0.11–0.74, P = 0.0089). A similar pattern was seen among the SULT1A1*1 homozygotes (relative risk = 0.48, 95% confidence interval = 0.21–1.12, P = 0.074). The combination of CYP2D6*4 and/or SULT1A1*1/*1 genotypes comprised 60% of the patients and showed a 62% decreased risk of distant recurrence with tamoxifen (relative risk = 0.38, 95% confidence interval = 0.19–0.74, P = 0.0041). Conclusion The present study suggests that genotype of metabolic enzymes might be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients. However, results are in contradiction to prior hypotheses and the present sample size is relatively small. Findings therefore need to be confirmed in a larger cohort.

Related Papers

• → CYP2D6 and tamoxifen: DNA matters in breast cancer(2009)322 cited
• → Coprescription of Tamoxifen and Medications That Inhibit CYP2D6(2010)141 cited
• → The Impact of CYP2D6 Genotyping on Tamoxifen Treatment(2010)23 cited
• → The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity(2015)13 cited
• Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.(2008)